Canaccord analyst Kyle Rose said Q1 results at Dexcom will likely raise near-term concerns about top-line growth and execution, but he believes investors should look past the first half of the year. Rose said there were several things in the Q1 results that strengthened his long-term Buy thesis, including stronger than expected patient demand, momentum outside of the U.S. that was ahead of scheduled, and the fact the company continues to take market share in the U.S. MDI market. Rose views post-earnings weakness as a buying opportunity. He lowered his price target to $90 from $95 on Dexcom shares and reiterated his Buy rating.